Hcp002, a class 1.1 anti infective new drug, gained clinical approval

Shaanxi Synthetic Pharmaceutical Co., Ltd (hereinafter referred to as "the company") has applied for a new chemical drug of category 1.1, "hcp002 and hcp002 for injection", which has obtained the approval document for clinical trials of drugs issued by the State Food and drug administration Hcp002 is a broad-spectrum triazole antifungal agent, which is mainly used to treat very serious and potentially life-threatening deep fungal infection Compared with the common drugs of the same kind, the product not only improves the quality of the drug preparation, prolongs the efficacy time, but also effectively reduces the toxicity and side effects of the drug, and significantly improves the safety of the drug The product will become the first-line drug and gold standard for the treatment of deep fungal infection after being launched in 2019, with an annual sales volume of 2 billion yuan On February 23, the company signed a contract with China Pharmaceutical city for the industrialization project of class 1.1 new drugs, with a total investment of 400 million yuan and an area of 80 mu Jiangsu tiandirenhe Biotechnology Co., Ltd was registered and established to build a R & D, production and sales base for the R & D, registration application, clinical trial and production and sales of class 1.1 new drugs It is understood that the company has signed hcp002 clinical trial research cooperation agreement with Nanjing Maituo Pharmaceutical Technology Co., Ltd., and will start phase I clinical trial soon Original announcement: